Related Experiment Videos
Abstract:
Since the introduction of cyclosporine, CNIs have formed the basis of immunosuppressive therapy in renal transplantation. The propensity of these agents to ultimately damage the very organs they were intended to protect was always recognized, but largely ignored due to their impressive ability to improve short-term outcomes. With the availability of equally powerful new immunosuppressive agents devoid of major nephrotoxicity, the irony of this situation has become all too apparent, and investigators are beginning to reevaluate the role of CNIs in renal transplantation. In this paper, we looked at strategies using MMF or sirolimus to reduce, withdraw, or replace CNIs in renal transplantation. Although MMF has proved effective in combination with CNIs, particularly in reducing acute rejection rates, its use as base therapy to allow CNI therapy to be withdrawn or eliminated is questionable. On the basis of initial trials, sirolimus holds promise for use as base therapy. To date, it is probably the only agent used in renal transplantation that provides immunosuppression comparable to cyclosporine or tacrolimus, which may someday allow sirolimus to replace. CNIs or allow early withdrawal of CNI therapy. Further study is needed to better clarify the role of sirolimus in improving long-term renal transplantation outcomes.
Insights
New immunosuppressive drugs like sirolimus show promise in reducing or replacing calcineurin inhibitors (CNIs) in renal transplantation, potentially improving long-term outcomes by minimizing organ damage.
Area of Science:
- Nephrology
- Immunology
- Transplantation Medicine
Background:
- Calcineurin inhibitors (CNIs) have been the cornerstone of immunosuppression in renal transplantation, despite their known nephrotoxicity.
- The development of novel immunosuppressive agents necessitates a reevaluation of the role of CNIs.
Purpose of the Study:
- To explore strategies for reducing, withdrawing, or replacing CNIs in renal transplantation using mycophenolate mofetil (MMF) or sirolimus.
- To assess the potential of MMF and sirolimus in improving long-term renal transplant outcomes.
Main Methods:
- Review of strategies involving MMF and sirolimus for CNI minimization or withdrawal in renal transplant recipients.
- Analysis of existing clinical trial data on the efficacy and safety of MMF and sirolimus in this context.
Main Results:
- MMF has shown efficacy in combination with CNIs for reducing acute rejection but its role in CNI withdrawal is uncertain.
- Sirolimus demonstrates potential as a base immunosuppressive therapy, offering comparable efficacy to CNIs and possibly allowing for their early withdrawal.
Conclusions:
- Sirolimus may offer a viable alternative to CNIs in renal transplantation, potentially improving long-term graft survival by mitigating nephrotoxicity.
- Further research is required to fully elucidate the long-term benefits of sirolimus-based immunosuppression in renal transplantation.